CLINICAL TRIALS PROFILE FOR FEMARA

505(b)(2) Clinical Trials for Femara

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT02520063 ↗	Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer	Active, not recruiting	Novartis Pharmaceuticals	Phase 1/Phase 2	2016-02-01	This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.
New Combination	NCT02520063 ↗	Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer	Active, not recruiting	Tracon Pharmaceuticals Inc.	Phase 1/Phase 2	2016-02-01	This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.
New Combination	NCT02520063 ↗	Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer	Active, not recruiting	University of Alabama at Birmingham	Phase 1/Phase 2	2016-02-01	This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.

All Clinical Trials for Femara

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	Cancer and Leukemia Group B	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	Eastern Cooperative Oncology Group	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	International Breast Cancer Study Group	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	North Central Cancer Treatment Group	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	Southwest Oncology Group	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.

Clinical Trial Conditions for Femara

Condition Name

Condition Name for Femara
Intervention	Trials
Breast Cancer	62
Metastatic Breast Cancer	11
Polycystic Ovary Syndrome	10
Breast Neoplasms	10

Condition MeSH

Condition MeSH for Femara
Intervention	Trials
Breast Neoplasms	119
Carcinoma	20
Polycystic Ovary Syndrome	14
Infertility	12

Clinical Trial Locations for Femara

Trials by Country

Trials by Country for Femara
Location	Trials
United States	678
Canada	43
Spain	22
Egypt	19
Ireland	14

Trials by US State

Trials by US State for Femara
Location	Trials
Texas	37
California	31
Florida	27
Massachusetts	25
Washington	23

Clinical Trial Progress for Femara

Clinical Trial Phase

Clinical Trial Phase for Femara
Clinical Trial Phase	Trials
PHASE3	2
PHASE1	1
Phase 4	23

Clinical Trial Status

Clinical Trial Status for Femara
Clinical Trial Phase	Trials
Completed	79
Recruiting	37
Active, not recruiting	26

Clinical Trial Sponsors for Femara

Sponsor Name

Sponsor Name for Femara
Sponsor	Trials
National Cancer Institute (NCI)	39
Novartis Pharmaceuticals	16
Novartis	15

Sponsor Type

Sponsor Type for Femara
Sponsor	Trials
Other	265
Industry	94
NIH	45

Clinical Trials Update, Market Analysis, and Projection for Femara

Last updated: October 30, 2025

---

Introduction

Femara (letrozole), authored by Novartis, is a well-established non-steroidal aromatase inhibitor primarily used in breast cancer treatment and hormonally-responsive breast cancer management. Approved by the U.S. Food and Drug Administration (FDA) in 1997, Femara has become a cornerstone in estrogen receptor-positive (ER+) breast cancer therapies, especially in postmenopausal women. As the therapeutic landscape evolves with emerging treatments and personalized medicine, understanding Femara’s clinical development trajectory, market positioning, and future outlook is essential for stakeholders.

---

Clinical Trials Update for Femara

Historical Context and Established Data

Femara’s initial approval was rooted in numerous pivotal clinical trials, notably the BIG 1-98 trial, which demonstrated superior efficacy of letrozole over tamoxifen as an adjuvant therapy for ER+ breast cancer in postmenopausal women. The long-term data from these trials continue to inform treatment guidelines and clinical decision-making.

Recent and Ongoing Trials

Despite its long-standing presence, Femara remains an active player in clinical research, primarily focusing on expanded indications, combination therapies, and resistance mechanisms:

• Combination with Targeted Agents: Multiple trials evaluate Femara alongside CDK4/6 inhibitors (e.g., palbociclib, abemaciclib) to enhance efficacy in early and metastatic hormone receptor-positive breast cancer. For instance, the NATALEE trial investigates letrozole combined with CDK4/6 inhibitors in early-stage disease, aiming to reduce recurrence rates.

• Resistance and Biomarker Studies: Ongoing research examines biomarkers predictive of resistance to aromatase inhibitors, with some trials exploring Femara’s role in overcoming endocrine therapy resistance.

• Extended Adjuvant Therapy: Trials like the SOLE study assess extended aromatase inhibitor therapy durations, including Femara, to determine optimal treatment length for prolonged disease-free survival.

New Formulations and Delivery Methods

While systemic oral administration remains standard, research investigates novel formulations—for example, bioavailability improvements or supportive therapies to mitigate side effects like osteoporosis and arthralgia. These efforts aim to optimize patient adherence and quality of life.

Regulatory and Labeling Updates

Recently, the European Medicines Agency (EMA) approved expansions in Femara’s label, especially emphasizing its use in combination therapy regimens and extended adjuvant settings based on ongoing trial data.

---

Market Analysis of Femara

Market Presence and Revenue Streams

As of 2023, Femara continues to generate significant revenue within Novartis’ oncology portfolio. Its global market is characterized by:

• Established Leadership in ER+ Breast Cancer: Femara remains one of the leading aromatase inhibitors, with a strong footprint in North America, Europe, and parts of Asia.

• Market Penetration: Despite the advent of newer agents like CDK4/6 inhibitors and the availability of generic aromatase inhibitors (e.g., anastrozole, exemestane), Femara retains a robust market share, especially in countries with stringent drug approval protocols and physician preferences for established therapies.

• Generic Competition: The patent exclusivity expired in many jurisdictions, leading to competition from generics, which has impacted pricing strategies but sustained volume sales.

Segment and Usage Trends

• Adjuvant Setting Dominance: The majority of Femara’s prescriptions are for adjuvant therapy in early-stage ER+ breast cancer patients post-surgery.

• Metastatic Disease: Femara is frequently prescribed for advanced or metastatic hormone-sensitive breast cancer, especially in patients intolerant to other therapies.

• Combination Regimens: The rising adoption of combination therapies with targeted agents has expanded Femara’s utility, although cost considerations influence prescribing patterns.

Market Drivers and Challenges

Drivers:

• Growing global incidence of breast cancer
• Clinical guideline endorsements
• Expanded indications and combination therapies
• High efficacy and established safety profile

Challenges:

• Competition from generics and newer targeted therapies
• Side-effect management, including osteoporosis and cardiovascular risks
• Market saturation in mature markets

---

Market Projection and Future Outlook

Forecast Overview (2023–2030)

Based on current trends, the Femara market is expected to experience moderate growth driven by ongoing clinical research, especially in combination regimens and extended adjuvant therapy:

• Compound Annual Growth Rate (CAGR): Estimated at 3-5%, considering patent expirations, generic competition, and evolving treatment paradigms.

• Geographic Expansion: Emerging markets (e.g., Asia-Pacific, Latin America) are projected to contribute substantially to sales growth due to increasing breast cancer prevalence and expanding healthcare infrastructure.

Influence of Emerging Therapeutics

The entry of novel agents such as oral selective estrogen receptor degraders (SERDs) and combination therapies integrating CDK4/6 inhibitors will influence Femara’s market share:

• Combination therapy adoption is expected to rise, bolstering Femara’s sales when paired with targeted agents.
• Real-world adoption of extended therapy could prolong usage periods, sustaining demand.

Impact of Personalized Medicine

Genomic and biomarker-driven approaches are poised to refine patient selection, predicting resistance to aromatase inhibitors. Femara’s future sales may depend on its integration into tailored treatment algorithms, emphasizing its role in personalized oncology.

Regulatory and Policy Factors

• Pricing and reimbursement policies in different jurisdictions will significantly influence market access.
• Continued clinical evidence supporting extended use and combination efficacy will underpin regulatory decisions favoring Femara.

---

Key Takeaways

• Clinical development remains robust: Femara’s ongoing trials predominantly focus on combination strategies and resistance management, securing its relevance in breast cancer therapy.
• Market dominance persists but faces competition: Despite generic threats, Femara maintains a strong position owing to established efficacy, clinician familiarity, and guideline endorsements.
• Growth opportunities are tied to combination therapies: Synergistic regimens with targeted agents and personalized medicine approaches offer promising avenues for sustaining sales.
• Emerging markets and extended therapy indications drive expansion: As breast cancer incidence rises globally, particularly in Asia and Latin America, Femara’s footprint is expected to grow.
• Strategic adaptation is essential: To capitalize on future opportunities, stakeholders should focus on differentiating Femara through evidence-based applications, optimizing therapy durations, and integrating biomarker-driven approaches.

---

Frequently Asked Questions

Q1: What are the primary indications for Femara?
A: Femara is approved for the treatment of hormone receptor-positive early and metastatic breast cancer in postmenopausal women, primarily as an adjuvant therapy and for advanced disease management.

Q2: How does Femara compare with other aromatase inhibitors?
A: Femara has demonstrated superior efficacy in specific clinical trials, such as BIG 1-98, compared to tamoxifen. It is comparable to other aromatase inhibitors like anastrozole and exemestane, with differences mainly in side-effect profiles and clinician preference.

Q3: What are the main side effects associated with Femara?
A: Common adverse effects include joint pain, arthralgia, hot flashes, osteoporosis, and cardiovascular risks. Management involves monitoring bone health and symptomatic treatment.

Q4: What is the outlook for Femara’s place in future breast cancer treatments?
A: Femara’s role is expected to persist, especially within combination therapies and extended adjuvant treatments, leveraging ongoing clinical research and evolving treatment strategies.

Q5: Are there any new formulations or administration methods for Femara in development?
A: Currently, research is focused on optimizing combination regimens and managing side effects. No new formulations have been officially approved but are under investigation to improve efficacy and patient adherence.

---

References

1. [1] Biganzoli, L., et al. "Extended adjuvant therapy with aromatase inhibitors in breast cancer: Evidence and future directions." Nature Reviews Clinical Oncology, 2022.
2. [2] Novartis. "Femara (letrozole) label updates and prescribing information." EMA and FDA reports.
3. [3] GlobalData. "Breast cancer therapeutics market analysis and future valuation." 2023.
4. [4] Cardoso, F., et al. "Adjuvant endocrine therapy in postmenopausal breast cancer." The Lancet, 2021.
5. [5] Smith, I., et al. "Emerging role of combination therapies in HR+ breast cancer." Oncotarget, 2023.

---

Disclaimer: This article is for informational purposes only and does not replace professional medical advice or regulatory consultation.